Bladder cancer is a complex urological malignancy that arises from the lining of the bladder. It can range from early-stage, non-muscle-invasive tumours to more advanced, muscle-invasive cancers. High-risk bladder cancer refers to aggressive forms of the disease that have a higher likelihood of progression, recurrence, or spread to other parts of the body. These cases require specialised management and close monitoring.
The High-Risk Bladder Cancer Clinic at Singapore General Hospital's Department of Urology offers specialised care for patients with advanced or complex bladder cancer. We aim to advance the understanding of bladder cancer and find novel treatments to improve patient outcomes while keeping costs low and achieve value-based care.
Clinical Services
We offer alternative treatments such as the combination of gemcitabine and docetaxel for patients who have not responded to standard BCG therapy. This rescue therapy involves sequential administration of these drugs directly into the bladder.
Treatment Regime:
- Induction: Weekly for 6 weeks
- Maintenance: Monthly for up to 24 months
Clinical Research
Our clinic actively participates in clinical trials, providing patients access to innovative treatments not yet widely available. We continuously seek to improve outcomes through research-driven approaches.
Translational Research
We conduct molecular studies on tumour tissues to enhance our understanding of bladder cancer. Our research aims to:
- Predict treatment responses
- Develop treatment prediction aids for tailored, cost-effective, and oncologically sound management plans
